Bio-Techne
TECH
271 hedge funds and large institutions have $3.72B invested in Bio-Techne in 2017 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 114 increasing their positions, 93 reducing their positions, and 25 closing their positions.
31% more call options, than puts
Call options by funds: $732K | Put options by funds: $559K
23% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 93
6.1% more ownership
Funds ownership: 385.97% → 392.07% (+6.1%)
0% more capital invested
Capital invested by funds: $3.7B → $3.72B (+$15.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
4% less funds holding
Funds holding: 281 → 271 (-10)
Top Buyers
| 1 |
BlackRock
New York
|
+$359M |
| 2 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
+$74.2M |
| 3 |
Neuberger Berman Group
New York
|
+$30.5M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$27.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.8M |
Top Sellers
TECH Hedge Fund Activity: Q1 2017 in Review
271 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Bio-Techne (TECH) for Q1 2017, worth a combined $3.72B — up 0.43% from $3.7B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of TECH and 24 opened new positions — a net loss of 1 holder — while 93 trimmed existing stakes and 114 added.
The largest buyer was BlackRock, adding an estimated $359M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $35.7M.
- 271 institutional investors held Bio-Techne (TECH) as of Q1 2017, down from 281 in Q4 2016.
- Funds reported $3.72B of Bio-Techne stock for Q1 2017, up 0.43% quarter-over-quarter.
- 24 funds opened new Bio-Techne positions in Q1 2017 and 25 closed out, a net change of -1 holder.
- The largest Bio-Techne buyer in Q1 2017 was BlackRock, an estimated $359M added.
- The largest Bio-Techne seller in Q1 2017 was Columbia Wanger Asset Management, an estimated $35.7M sold.
Based on aggregated 13F filings for Q1 2017.